MCC Propellant Testing. CPHI & PODD conferences.
Are you redeveloping your pMDI products to contain more environmentally friendly, low global warming potential propellants?
At BDD, we specialise in scintigraphy, a radiolabelling technique that provides the clinical data necessary to prove that changes in propellant does not impact lung function. Our team have been performing MCC studies for over ten years, helping our partners develop new, safer inhalation products.
We are excited to announce that Dr. Carol Thomson, CEO at BDD, will once again be attending this year’s CPhI. As a leader in innovative drug delivery technologies, Dr. Thomson looks forward to discussing new opportunities and advancements in pharmaceutical development. If you’re attending, be sure to connect with her to explore how BDD can support your development needs. We look forward to seeing you there!
Darren Quinn is speaking at PODD – Boston Oct 28 – 29, 2024
Development and Pharmacoscintigraphic Analysis of Novel Dual-pulse Fixed Dose Combination Tablet
Darren Quinn is the Head of Business Development at BDD Pharma where he leads the global business development and licensing activities.
Darren earned a master’s degree in chemistry from the University of Strathclyde in Glasgow, Scotland, where his industry experience began with a placement as an Organic Chemist at Technologie Servier. He furthered his career at Lonza and Next Pharma, where he specialized in oral solid dosage (OSD) formulation development of BCS Class II and IV molecules.
At BDD, Darren leverages his commercial and scientific expertise to address complex drug development challenges for BDD’s partners and clients.
>Request a meeting with Darren
For over 20 years, BDD has provided customized services for clinical trials across pharmaceutical, biotech, and medical device sectors.
